trial

Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis

NCTId NCT00628290
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 42 (estimated)
Sponsored by University of Cologne
Primary completion 2004-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
42 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2002-10
Primary completion
2004-11
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
CannabidiolAmisulpride

Sponsors

University of CologneLead Sponsor

Investigators

1
Franz-Markus Leweke, MDPrincipal Investigator

Sites

1 total
Cologne, Germany

Linked catalysts

1
Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic P — primary completion2004-11

Facts & assertions

4 sourced
Enrollment
42
Phase
PHASE2
Primary Completion Date
2004-11
Status
COMPLETED
relationships
The graph out of here
drug
Cannabidiol
drug
Amisulpride
drug
lead_sponsor
University of Cologne
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Franz-Markus Leweke, MD
person